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Abstract
The use of machine learning (ML) in health care raises numerous ethi-
cal concerns, especially as models can amplify existing health inequities.
Here, we outline ethical considerations for equitable ML in the advance-
ment of health care. Specifically, we frame ethics of ML in health care
through the lens of social justice. We describe ongoing efforts and out-
line challenges in a proposed pipeline of ethical ML in health, ranging
from problem selection to post-deployment considerations. We close by
summarizing recommendations to address these challenges.
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1. INTRODUCTION
As machine learning (ML) models proliferate into many aspects of our lives, there is growing
concern regarding their ability to inflict harm. In medicine, excitement about human-level
performance (1) of ML for health is balanced against ethical concerns, such as the potential
for these tools to exacerbate existing health disparities (2, 3, 4, 5). For instance, recent
work has demonstrated that state-of-the-art clinical prediction models underperform on
women, ethnic and racial minorities, and those with public insurance (6). Other research has
shown that when popular contextual language models are trained on scientific articles, they
complete clinical note templates to recommend “hospitals” for violent white patients and
“prison” for violent Black patients (7). Even more worrisome, health care models designed
to optimize referrals to long-term care-management programs for millions of patients were
found to exclude Black patients with similar health conditions compared to white patients
from care management programs (8).
A growing body of literature wrestles with the social implications of machine learning
and technology. Some of this work, referred to as critical data studies, is from a social
science perspective (9, 10), whereas other work leads with a technical and computer science
perspective (11, 12, 13). While there is scholarship addressing social implications and
algorithmic fairness in general, there has been less work at the intersection of health, ML,
and fairness (14, 15, 16), despite the potential life-or-death impacts of those models (8, 17).
Machine learning
(ML): The study of
computer algorithms
that improve
automatically
through experience
ML model: An
algorithm that has
been trained on data
for a specific use
case
Algorithm: A finite
sequence of
well-defined
instructions used to
solve a class of
problems
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Problem 
Selection
Data 
Collection
Outcome 
Definition
Algorithm 
Development
Post-Deployment 
Considerations
Disparities in funding 
and problem 
selection priorities 
are an ethical 
violation of principles 
of justice.
Focus on convenience 
samples can exacerbate 
existing disparities in 
marginalized and 
underserved populations, 
violating do-no-harm 
principles. 
Biased clinical 
knowledge, implicit power 
differentials, and social 
disparities of the 
healthcare system 
encode bias in outcomes 
that violate justice 
principles. 
Default practices, like 
evaluating 
performance on large 
populations, violate 
beneficence and 
justice principles when 
algorithms do not work 
for sub-populations.
Targeted, spot-check 
audits and lack of model 
documentation ignore 
systematic shifts in 
populations risks patient 
safety, furthering risk to 
underserved groups. 
Figure 1
We motivate the five steps in the ethical pipeline for health care model development. Each stage
contains considerations for ML where ignoring technical challenges violate the bioethical principle
of justice, either by exacerbating existing social injustices or by creating the potential for new
injustices between groups. Although this review’s ethical focus is on social justice, the challenges
that we highlight may also violate ethical principles such as justice and beneficence. We highlight
a few in this illustration.
While researchers looking to develop ethical ML models for health can begin by draw-
ing on bioethics principles (18, 19), these principles are designed to inform clinical care
practices. How these principles could inform the ML model development pipeline remains
understudied. We note that there has been significant work on other important eth-
Ethical pipeline: The
model development
process and the
corresponding
ethical
considerations
Bioethics: The study
of ethical issues
emerging from
advances in biology
and medicine
Justice: The
principle that
obligates equitably
distributed benefits,
risks, costs, and
resources
Beneficence: The
principle that
requires that care be
provided with the
intent of doing good
for the patient
involved
Non-maleficence:
The principle that
forbids harm or
injury to the patient,
either through acts
of commission or
omission
ical issues that relate to ML and health, including reviews of consent and privacy (20),
which we do not address here. Instead, we focus on equity in ML models that operate on
health data. We focus primarily on differences between groups induced by, or related to,
the model development pipeline, drawing on both the bioethics principle of justice, and
the established social justice centering of public health ethics (21). Unjust differences in
quality and outcomes of health care between groups often reflect existing societal disparities
for disadvantaged groups. We consider other bioethics principles such as beneficence and
non-maleficence, but focus them primarily on groups of patients rather than on individuals.
We organize this review by describing the ethical considerations that arise at each step of
the pipeline during model development for ML in health (Figure 1), from research funding
to post-deployment. Here we motivate the ethical considerations in the pipeline with a case
study of Black mothers in the United States, who die in childbirth at a rate three times
higher than white women (22). This inequity is unjust because it connects to a history
of reproductive injustices faced by Black women in the United States, from gynecological
experimentation on enslaved women to forced sterilizations (23, 24).
1. This disparity occurs in part during problem selection because maternal mortality
is an understudied problem (25).
2. Even after accounting for problem selection, data collection from hospitals may dif-
fer in quality and quantity. For example, 75% of Black women give birth at hospitals
that serve predominantly Black patients (26) but Black-serving hospitals have higher
rates of maternal complications than other hospitals (27).
3. Once data are collected, the choice of outcome definition can obscure underlying
issues, e.g., differences in clinical practice. General model outcome definitions for
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maternal health complications might overlook conditions specific to Black mothers,
e.g., fibroids (28).
4. During algorithm development, models may not be able to account for the con-
founding presence of societal bias. Black mothers in the wealthiest neighborhoods in
Brooklyn, New York have worse outcomes than white, Hispanic, and Asian mothers
in the poorest ones, demonstrating a gap despite factors that should improve Black
mothers’ outcomes — living in the same place, and having a higher income — likely
due to societal bias that impacts Black women (29).
5. Finally, after a model is trained, post-deployment considerations may not fully
consider the impact of deploying a biased prediction model into clinical settings
that have large Black populations. Because Black women have a heightened risk
of pregnancy-related death across income and education levels (30), a biased predic-
tion model could potentially automate policies or risk scores that disadvantage Black
mothers.
Model outcome: The
output of interest for
predictive models
Deployment: The
process through
which a machine
learning model is
integrated into an
existing production
environment
Risk score: A
calculated number
denoting the
likelihood of adverse
event
We organize the rest of this review sequentially expanding on each of the five steps in
the pipeline described above and in Figure 1. First, we look at problem selection, and
explain how funding for ML for health research can lead to injustice. We then examine
how data collection processes in funded research can amplify inequity and unfairness. We
follow this by exploring outcome definition and algorithm building, listing the multitude
of factors that can impact model performance, and how these differences in performance
relate to issues of justice. We close with audits that should be considered for more robust
and just deployments of models in health, and recommendations to practitioners for ethical,
fair, and just ML deployments.
2. PROBLEM SELECTION
There are many factors that influence the selection of a research problem, from interest
to available funding. However, problem selection can also be a matter of justice if the
research questions that are proposed, and ultimately funded, focus on the health needs of
advantaged groups. Below we provide examples of how disparities in research teams and
funding priorities exacerbate existing socioeconomic, racial, and gender injustices.
2.1. Global Health Injustice
The “10/90” gap refers to the fact that the vast majority of health research dollars are spent
on problems that affect a small fraction of the global population (31, 32). Diseases that are
most common in lower-income countries receive far less funding than diseases that are most
common in high-income countries (33) (relative to the number of individuals they affect).
As an example, 26 poverty-related diseases account for 14% of the global disease burden, but
receive only 1.3% of global health-related research and development expenditure. Nearly
60% of the burden of poverty-related neglected diseases occurs in Western and Eastern sub-
Saharan Africa as well as South Asia. Malaria, tuberculosis, and HIV/AIDS all have shares
of global health-related research and development expenditure that are at least five times
smaller than their share of global disease burden (33). This difference in rates of funding
represents an injustice because it further exacerbates the disadvantages faced by Global
South populations. While efforts like the “All Of Us” Project (34) and the 23andMe’s
Call for Collaboration (35) seek to collect more inclusive data, these efforts have come
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under criticism for not reflecting global health concerns, particularly among Indigenous
groups (36). Global South:
Countries on one
side of the
North–South divide,
the other side being
the countries of the
Global North
2.2. Racial Injustice
Racial bias affects which health problems are prioritized and funded. For example, sickle
cell disease and cystic fibrosis are both genetic disorders of similar severity, but sickle cell
disease is more common in Black patients, while cystic fibrosis is more common in white
patients. In the United States (US), however, cystic fibrosis receives 3.4 times more funding
per affected individual from the US National Institutes of Health (NIH), the largest funder
of US clinical research, and hundreds of times more private funding (37). The disparities
in funding persist despite the 1972 Sickle Cell Anemia Control Act, which recognizes that
sickle cell has been neglected by the wider research community. Further, screening for sickle
cell disease is viewed by some as unfair targeting (38), and Black patients with the disease
who seek treatment are often maligned as drug abusers (39).
2.3. Gender Injustice
Women’s health conditions like endometriosis are poorly understood; as a consequence,
even basic statistics like the prevalence of endometriosis remain unknown, with estimates
ranging from 1% to 10% of the population (40, 41). Similarly, the menstrual cycle is stig-
matized and understudied (40, 42), producing a dearth of understanding that undermines
the health of half the global population. Basic facts about the menstrual cycle — in-
cluding which menstrual experiences are normal and which are predictive of pathology —
remain unknown (40). This lack of focus on the menstrual cycle propagates into clinical
practice and data collection despite evidence that it affects many aspects of health and
disease (43, 44). Menstrual cycles are also not often recorded in clinical records and global
health data (40). In fact, the NIH did not have an R01 grant, the NIH’s original and
historically oldest grant mechanism, relating to the influence of sex and gender on health
and disease until 2019 (45). Notably, recent work has moved to target such understudied
problems via ambulatory women’s health-tracking mobile apps. These crowd-sourcing ef-
forts stand to accelerate women’s health research by collecting data from cohorts that are
orders of magnitude larger than those used in previous studies (40).
2.4. Diversity of the Scientific Workforce
The diversity of the scientific workforce profoundly influences the problems studied, and
contributes to the biases in problem selection (46). Research shows that scientists from
underrepresented racial and gender groups tend to prioritize different research topics. They
produce more novel research, but their innovations are taken up at lower rates (47). Female
scientists tend to study different scientific subfields, even within the same larger field — for
example, within sociology, they have been historically better-represented on papers about
sociology of the family or early childhood (48) — and express different opinions about
ethical dilemmas in computer science (49). Proposals from white researchers in the US are
more likely to be funded by the NIH than proposals from Black researchers (50, 51), which
in turns affects what topics are given preference. For example, a higher fraction of NIH
proposals from Black scientists study community and population-level health (50). Overall,
this evidence suggests that diversifying the scientific workforce will lead to problem selection
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that more equitably represents the interests and needs of the population as a whole.
3. DATA COLLECTION
The role of health data is ever-expanding, with new data sources routinely being integrated
into decision-making around health policy and design. This wealth of high-quality data,
coupled with advancements in ML models, has played a significant role in accelerating
the use of computationally informed policy and practice to strengthen health care and
delivery platforms. Unfortunately, data can be biased in ways that have (or can lead to)
disproportionate negative impacts on already marginalized groups. First, data on group
membership can be completely absent. For instance, countries such as Canada and France
do not record race and ethnicity in their nationalized health databases (52, 53), making
it impossible to study race-based disparities and hypotheses around associations of social
determinants of health. Second, data can be imbalanced. Recent work on acute kidney
injury achieved state-of-the-art prediction performance in a large dataset of 703,782 adult
patients using 620,000 features; however, they note that model performance was lower in
female patients since female patients comprised 6.38% of patients in the training data (54).
Other work has indicated that this issue can not be simply addressed by “pre-training” a
model in a more balanced data setting prior to fine-tuning on an imbalanced dataset (55).
This indicates that a model cannot be “initialized” with a balanced baseline representation
which ameliorates issues of imbalance in downstream tasks, and suggests we must solve this
problem at the root, be it with more balanced are comprehensive data, specialty learning
algorithms, or combinations therein.Finally, while some sampling biases can be recognized
and possibly corrected, others may be difficult to correct. For example, work in medical
imaging has demonstrated that models may overlook unforeseen stratification of conditions,
like rare manifestations of diseases, which can result in harm in clinical settings (56, 16).
In this section, we discuss common biases in data collection. We consider two types of
processes that result in a loss of data. First, processes that affect what kind of information
is collected, or heterogenous data loss, across varying input types. For example, clinical
trials with aggressive inclusion criteria or social media data that reflects those with access
to devices. Second, we examine processes that affect whether an individual’s information is
collected, or population-specific data losses, where individuals are impacted by their pop-
ulation type, often across data input categories. For example, undocumented immigrants
may fear deportation if they participate in health care systems.
3.1. Heterogeneous Data Losses
Some data loss is specific to the data type, due to assumptions about noise that may have
been present during the collection process. However, data noise and missingness can cause
unjust inequities that impact populations in different ways. We cover four main data types:
randomized controlled trials (RCTs), electronic health care records (EHR), administrative
health data, and social media data.
Randomized Controlled Trials Randomized controlled trials are often run specifi-
cally to gather “unbiased” evidence of treatment effects. However, RCTs have notoriously
aggressive exclusion (or inclusion) criteria (57), which create study cohorts that are not
representative of general patient populations (58). In one study of RCTs used to define
asthma treatment, an estimated 94% of the adult asthmatic population would not have
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been eligible for the trials (59). There is a growing methodological literature designing
methods to generalize RCT treatment effects to other populations (60). However, current
empirical evidence indicates that such generalizations can be challenging given available
data or may require strong assumptions in practice.
Training data:
Information that a
ML model fits to
and learns patterns
from
Heterogeneous data
loss: The process
where data can be
lost in collection due
to data type
Population-specific
data loss: The
process where data
can be lost in
collection due to the
features of the
population
Data noise:
Meaningless
information added to
data that obscures
the underlying
information of the
data
Missingness: The
manner in which
data is absent from
a sample of the
population
Randomized
controlled trial
(RCT): A study in
which subjects are
allocated by chance
to receive one of
several interventions
Electronic health
record (EHR):
Digital version of a
patient’s clinical
history that is
maintained by the
provider over time
Intervention: A
treatment,
procedure, or other
action taken to
prevent or treat
disease, or improve
health in other ways
Electronic Health Records Much recent work in ML also leverages large electronic
health records data. EHR data are a complex reflection of patient health, health care
systems, and providers, where data missingness is a known, and meaningful, problem (61).
As one salient example, a large study of laboratory tests to model three-year survival
found that health care process features had a stronger predictive value than the patient’s
physiological feaures (62). Further, not all treatments investigated in RCTs can be easily
approximated in EHR (63).
Biases in EHR data may arise due to differences in patient populations, access to care,
or the availability of EHR systems (64). As an example, the widely-used MIMIC-III EHR
dataset includes most patients who receive care at the intensive care units in Beth Israel
Deaconess Medical Center (BIDMC), but this sample is obviously limited by which indi-
viduals have access to care at BIDMC, which has a largely white patient population (14).
In the United States, uninsured Black and Hispanic or Latin(o/x) patients, as well as His-
panic or Latin(o/x) Medicaid patients, are less likely to have primary care providers with
EHR systems, as compared to white patients with private insurance (65). Other work has
shown that gender discrimination in health care access has not been systematically studied
in India, primarily due to a lack of reliable data (66).
Administrative Health Records In addition to RCTs and EHR, health care billing
claims data, clinical registries, and linked health survey data are also common data sources
in population health and health policy research (67, 68), with known biases in which popu-
lations are followed, and who is able to participate. Translating such research into practice
is a crucial part of maintaining health care quality, and limited participation of minority
populations by sexual orientation and gender identity (69), race and ethnicity (70), and
language (71) can lead to health interventions and policies that are not inclusive, and can
create new injustices for these already marginalized groups.
Social Media Data Data from social media platforms and search-based research by
nature consists only of individuals with internet access (72). Even small choices like limiting
samples to those from desktop versus mobile platforms are a problematic distinction in non-
North American contexts (73). Beyond concerns about access to resources or geographic
limitations, data collection and scraping pipelines for most social media cohorts do not
yield a random sample of individuals. Further, the common practice of limiting analysis to
those satisfying a specified threshold of occurrence can lead to skewed data. As an example,
when processing the large volume of Twitter data (7.6 billion tweets) researchers may first
restrict to users who can be mapped to a US county (1.78 billion), then to those Tweets
that contain only English (1.64 billion tweets), and finally remove users who made less than
30 posts (1.53 billion) (74).
3.2. Population-specific Data Losses
As with data types, the modern data deluge does not apply equally to all communities. His-
torically underserved groups are often underrepresented, misrepresented, or entirely miss-
ing from health data that inform consequential health policy decisions. When individuals
from disadvantaged communities appear in observational datasets, they are less likely to be
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accurately captured due to errors in data collection and systemic discrimination. Larger ge-
nomics datasets often target European populations, producing genetic risk scores which are
more accurate in individuals of European ancestry than other ancestries (75). We note four
specific examples of populations that are commonly impacted: low- and middle-income na-
tionals, transgender and gender non-conforming individuals, undocumented migrants, and
pregnant women.
Low- and Middle-Income Nationals Health data are infrequently collected due to
resource constraints, and even basic disease statistic data such as prevalence of mortality
rates can be challenging to find for low- and middle-income nations (73). When data
are collected, it is not digitized, and often contains errors. In 2001, the World Health
Organization found that only 9 out of the 46 member states in Sub-Saharan Africa could
produce death statistics for a global assessment of the burden of disease, with data coverage
often less than 60% in these countries (76).
Transgender and Gender Non-conforming Individuals The health care needs and
experiences of transgender and gender non-conforming individuals are not well-documented
in datasets (77) because documented sex, not gender identity, is what is usually available.
However, documented sex is often discordant with gender identity for transgender and gen-
der non-conforming individuals. Apart from health documentation concerns, transgender
people are often concerned about their basic physical safety when reporting their identities.
In the US, it was only in 2016, with the release of the US Transgender Survey that there
was a meaningfully sized dataset — 28,000 respondents — to enable significant analysis
and quantification of discrimination and violence that transgender people face (77).
Undocumented Immigrants Safety concerns are important in data collection for
undocumented migrants, where socio-political environments can lead to individuals feeling
unsafe during reporting opportunities. When immigration policies limit access to public
services for immigrants and their families, these restrictions lead to spillover effects on clin-
ical diagnoses. As one salient example, autism diagnoses for Hispanic children in California
fell following aggressive federal anti-immigrant policies requiring citizenship verification at
hospitals (78).
Pregnant Women Despite pregnancy being neither rare nor an illness, the US contin-
ues to experience rising maternal mortality and morbidity rates. In the US, the maternal
mortality rate has more than doubled from 9.8 per 100,000 live births in 2000 to 21.5 in
2014 (79). Importantly, disclosure protocols recommend suppression of information in na-
tionally available datasets when the number of cases or events in a data “cell” is low, to
reduce the likelihood of a breach of confidentiality. For example, the US Centers for Disease
Control suppresses numbers for counties with fewer than 10 deaths for a given disease (80).
Although these data omissions occur because of patient privacy, such censoring on the de-
pendent variable introduces particularly pernicious statistical bias and, as a result, much
remains to be understood about what community, health facility, patient, and provider-level
factors drive high mortality rates.
Censoring: The
mechanism through
which data values
are removed from
observation
4. OUTCOME DEFINITION
The next step in the model pipeline is to define the outcome of interest for a health care task.
Even seemingly straightforward tasks like defining whether a patient has a disease can be
skewed by how prevalent diseases are, or how they manifest in some patient populations. For
example, a model predicting if a patient will develop heart failure will need labeled examples
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both of patients who have heart failure, and patients without heart failure. Choosing
these patients can rely on parts of the EHR that may be skewed due to lack of access to
care, or abnormalities in clinical care: e.g., economic incentives may alter diagnosis code
logging (81), clinical protocol affects the frequency and observation of abnormal tests (62),
historical racial mistrust may delay care and affect patient outcomes (82), and naive data
collection can yield inconsistent labels in chest X-rays (56). Such biased labels, and the
resulting models, may cause clinical practitioners to allocate resources poorly.
We discuss social justice considerations in two examples of commonly modelled health
care outcomes: clinical diagnosis and health care costs. In each example, it is essential that
model developers choose a reliable proxy and account for noise in the outcome labels as
these choices can have a large impact on performance and equity of the resulting model.
4.1. Clinical Diagnosis
Clinical diagnosis is a fundamental task for clinical prediction models, e.g., models for
computer-aided diagnosis from medical imaging. In clinical settings, researchers often select
patient disease occurrence as the prediction label for models. However, there are many
options for the choice of a disease occurrence label. For example, the outcome label for
developing cardiovascular disease could be defined through the occurrence of specific phrases
in clinical notes. However, women can manifest symptoms of acute coronary syndrome
differently (83) and receive delayed care as a result (84), which may then manifest in
diagnosis labels derived from the clinical notes being gender-skewed. Because differences
in label noise results in disparities in model impact, researchers have the responsibility
to choose and improve disease labels, so that these inequalities do not further exacerbate
disparities in health.
Additionally, it is important to consider the health care system in which disease labels
are logged. For example, health care providers leverage diagnosis codes for billing purposes,
not clinical research. As a result, diagnosis codes can create ambiguities because of overlap
and hierarchy in codes. Moreover, facilities have incentives to under-report (81) and over-
report (85, 86) outcomes, yielding differences in model representations.
Label noise: Errors
or otherwise
obscuring
information that
affects the quality of
the labels
Diagnosis code: A
label in patient
records of disease
occurrence, which
may be subject to
misclassification,
used primarily for
billing purposes
Recent advances in improving disease labels target statistical corrections based on esti-
mates of the label noise. For instance, a positive label may be reliable, but the omission of a
positive label could either indicate a negative label (i.e., no disease) or merely a missed pos-
itive label. Methods to address the positive-unlabeled setting use estimated noise rates (87)
or hand-curated labels that are strongly correlated with positive labels, known also as
“silver-standard” labels, from clinicians (88). Clinical analysis of sources of error in disease
labels can also guide improvements (89) and identify affected groups (56).
4.2. Health Care Costs
Developers of clinical models may choose to predict health care costs, meaning the ML model
seeks to predict which patients will cost the health care provider more in the future. Some
model developers may use health care costs as a proxy for future health needs to guide
accurate targeting of interventions (8), with the underlying assumption that addressing
patients with future health need will limit future costs. Others may explicitly want to
understand patients who will have high health care cost to reduce the total cost of health
care (90). However, because socioeconomic factors affect both access to health care and
access to financial resources, these models may yield predictions that exacerbate inequities.
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For model developers seeking to optimize for health need, health care costs can deviate
from health need on an individual level because of patient socioeconomic factors. For in-
stance, in a model used to allocate care management program slots to high-risk patients,
the choice of future health care costs as a predictive outcome led to racial disparities in
patient allocation to the program (8). Health care costs can differ from health need on
an institutional level due to underinsurance and undertreatment within the patient popu-
lation (91). After defining health disparities as all differences except those due to clinical
need and preferences, researchers have found racial disparities in mental health care. Specif-
ically, white patients had higher rates of initiation of treatment for mental health compared
to Black and Hispanic or Latin(o/x) patients. Because the analysis controls for health
need, the disparities are solely a result of differences in health care access and systemic
discrimination (92).
Addressing issues that arise from the use of health care costs depends on the setting of
the ML model. In cases where health need is of highest importance, a natural solution is
to choose another outcome definition besides health care costs, e.g., the number of chronic
diseases as a measure of health need. If a model developer is most concerned with cost, it is
possible to correct for health disparities in predicting health care costs by building fairness
considerations directly into the predictive model objective function (93). Building these
types of algorithmic procedures is further discussed in Section 5.
5. ALGORITHM DEVELOPMENT
Algorithm development considers the construction of the underlying computation for the
ML model and presents a major vulnerability and opportunity for ethical ML in health
care. Just as data are not neutral, algorithms are not neutral. A disproportionate amount
of power lies with research teams who, after determining the research questions, make
decisions about critical components of an algorithm such as the loss function (94, 46). In
the case of loss functions, common choices like the L1 absolute error loss and L2 squared
error loss do not target the same conditional functions of the outcome, instead minimizing
the error in the median and mean respectively. Using a surrogate loss (e.g., hinge loss for
Loss function: The
relation that
determines the error
between algorithm
output and given
label, which the
algorithm uses to
optimize
the error rate) can provide computational efficiency, but it may not reflect the ethical criteria
that we truly care about. Recent work has shown that models trained with a surrogate loss
may exhibit “approximation errors” that disproportionately affect undersampled groups in
the training data (95). Similarly, one might choose to optimize the worst-case error across
groups as opposed to the average overall error. Such choices may seem purely technical, but
reflect value statements about what should be optimized, potentially leading to differences
in performance among marginalized groups (96).
In this section, we review several crucial factors in model development that potentially
impact ethical deployment capacity: understanding (and accounting for) confounding, fea-
ture selection, tuning parameters, and defining “fairness” itself.
5.1. Understanding Confounding
Developing models that use sensitive attributes without a clear causal understanding of
their relationship to outcomes of interest can significantly affect model performance and
interpretation. This is relevant to algorithmic problems focused on prediction, not just
causal inference. “Confounding” features — i.e., those features that influence both the
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independent variables and the dependent variable — require careful attention. The vast
majority of models learn patterns based on observed correlations between training data,
even when such correlations do not occur in test data. For instance, recent work has
demonstrated that classification models designed to detect hair color learn gender-biased
decision boundaries when trained on confounded data, i.e., if women are primarily blond
in training data, the model incorrectly associates gender with the hair label in test samples
(97).
Confounding: The
condition in which a
feature influences
both the dependent
variable and
independent
variable, causing a
spurious association
Test data: Unseen
information that a
model predicts on
and is evaluated
against
As ML methods are increasingly used for clinical decision support, it is critical to ac-
count for confounding features. In one canonical example, asthmatic patients presenting
with pneumonia are given aggressive interventions that ultimately improve their chances of
survival over non-asthmatic patients (98). When the hospital protocol assigned additional
treatment to patients with asthma, those patients had improved outcomes. Thus the treat-
ment policy was a confounding factor that altered the data in a seemingly straight-forward
prediction task such that patients with asthma were erroneously predicted by models to
have lower risk of dying from pneumonia.
Simply controlling for confounding features by including them as features in classifica-
tion or regression models may be insufficient to learn reliable models because features can
have a mediating or moderating effect (post-treatment effect on outcomes of interest) and
have to be incorporated differently into model design (99).
Modern ML and causal discovery techniques can identify sources of confounding at
scale (100), although validation of such methods can be challenging because of the lack
of counterfactual data. ML methods have also been proposed to estimate causal effects
from observational data (101, 102). In practice, when potential hidden confounding is sus-
pected, either mediating features or proxies can be leveraged (103, 99) or sensitivity anal-
ysis methods can be used to determine potential sources of errors in effect estimates (104).
Data-augmentation and sampling methods may also be used to mitigate effects of model
confounding. For example, augmenting X-ray images with rotated and translated variants
can help train a model that is not sensitive to orientation of an image (105).
5.2. Feature Selection
With large-scale digitization of EHR and other sources, sensitive attributes like race and
ethnicity may be increasingly available (although prone to misclassification and missing-
ness). However, blindly incorporating factors like race and gender in a predictive model
may exacerbate inequities for a wide range of diagnostics and treatments (106). These
resulting inequities can lead to unintended and permanent embedding of biases in algo-
rithms used for clinical care. For example, vaginal birth after cesarean (VBAC) scores are
used to predict success of “trial of labor” of pregnant women with a prior cesarean section;
however, these scores explicitly include a race component as an input which reduces the
chance of VBAC success for Black and Hispanic women. Although researchers found that
previous observational studies showed correlation between racial identity and success of
trial of labor (107), the underlying cause of this association is not well-understood. Such
na¨ıve inclusion of race information could exacerbate disparities in maternal mortality. This
ambiguity calls race-based ‘correction’ in scores like VBAC into question (106).
Sensitive attribute:
A specified patient
feature (e.g., race,
gender) which is
considered
important for
fairness
considerations
Stepwise regression:
A method of
estimation where
each feature is
sequentially
considered by
addition or
subtraction to the
existing feature set
Automation in feature selection does not eliminate the need for contextual understand-
ing. For example, stepwise regression is commonly used and taught as a technique for
feature selection despite known limitations (108). While specific methods have varying ini-
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tialization (e.g., start with an empty set of features or full set of features) and processing
steps (e.g., deletion vs. addition of features), most rely on p-values, R2, or other global fit
metrics to select features. Weaknesses of stepwise regressions include the misleading nature
of p-values and the final set depending on if and when features were considered (109). In
ML, penalized regressions like lasso regression are popular for automated feature selection,
but the lasso trades potential increases in estimation bias for reductions in variance by
shrinking some feature coefficients to zero. Features selected by lasso may be co-linear with
other features not selected (110). Over-interpretation of the selected features in any auto-
mated procedures should therefore be avoided in practice given these pitfalls. Researchers
should also consider the humans-in-the-loop framework where incorporation of automated
procedures is blended with investigator knowledge (111).
5.3. Tuning Parameters
There are many tuning parameters that may be set a priori or selected via cross-
validation (110). These range from the learning rate in a neural network to the minimum
size of the terminal leaves in a random forest. In the latter example, default settings in R
for classification will allow trees to grow until there is just one observation in a terminal
leaf. This can lead to overfitting the model to the training data and a loss of generalizabil-
ity to the target population. Lack of generalizability is a central concern for ethical ML
given the previously discussed issues in data collection and study inclusion. When data
lack diversity and are not representative of the target population where the model would be
deployed, overfitting algorithms to this data has the potential to disproportionately harm
marginalized groups (112). Using cross-validation to select tuning parameters does not au-
tomatically solve these problems as cross-validation still operates with respect to an a priori
chosen optimization target.
Tuning parameters:
Algorithm
components used for
prediction that are
tuned toward solving
an optimization
problem
AUC: A measure of
the sensitivity and
specificity of a
model for each
decision threshold
AUPRC: A measure
of precision and
recall of a model for
each decision
threshold
Calibration: A
measure of how well
ML risk estimates
reflect true risk
5.4. Performance Metrics
There are many commonly used performance metrics for model evaluation such as area
under the receiver-operating characteristic (AUC), precision-recall curves (AUPRC), and
calibration (113). However, the appropriate metrics to optimize depend on intended use
case and relative value of true positives, false positives, true negatives, and false negatives.
Not only can AUC be misleading when considering other global fit metrics (e.g., high AUC
masking weak true positive rate), but it does not describe the impact of the model across
selected groups. Further, even “objective” metrics and scores can be deeply flawed, and
lead to over or under-treatment of minorities if blindly applied (114). Note that robust
reporting of results should include an explicit statement of other non-optimized metrics,
including the original intended use case, the training cohort and case, or level of model
uncertainty.
5.5. Group Fairness Definition
The specific definition of fairness for a given application often impacts the choice of a
loss function, and therefore the underlying algorithm. Individual fairness imposes classifier
performance requirements that operate over pairs of individuals, e.g., similar individuals
should be treated similarly (115). Group fairness operates over “protected groups” (based on
some sensitive attribute) by requiring that a classifier performance metric be balanced across
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those groups. (116, 117). For instance, a model may be partially assessed by calculating
the true positive rate separately among rural and urban populations to ensure risk score
similarity. Regressions subject to group fairness constraints or penalties optimizing toward
joint global and group fit considerations have also been developed (118, 119, 93).
Performance metric:
Score or other
quantitative
representation of a
model’s quality and
ability to achieve
goals
Algorithmic fairness:
The study of
definitions and
methods related to
the justice of models
Group fairness: A
principle where
pre-defined patient
groups should
receive similar model
performance
Recent work has focused on identifying and mitigating violations of fairness definitions
in health care settings. While most of these algorithms have emerged outside the field of
health care, researchers have designed penalized and constrained regressions to improve
the performance of health insurance plan payment. This payment system impacts tens of
millions of lives in the United States and is known to undercompensate insurers for individ-
uals with certain health conditions, including mental health and substance use disorders, in
part because billing codes do not accurately capture diagnoses (120). Undercompensation
creates incentives for insurers exclude individuals with these health conditions from enroll-
ment, limiting their access to care. Regressions subject to group fairness constraints or
penalties were successful in removing nearly all undercompensation for a single group with
negligible impacts on global fit (93). Subsequent work incorporating multiple groups into
the loss function also saw improvements in undercompensation for the majority of groups
not included (121).
6. POST-DEPLOYMENT CONSIDERATIONS
Often the goal of model training is to ultimately deploy it in a clinical, epidemiological,
or policy service. However, deployed models can have lasting ethical impact beyond the
model performance measured in development. For example, in the inclusion of race in the
clinical risk scores described earlier that may lead to chronic over- or under-treatment (106).
Here we outline considerations for robust deployment by highlighting the need for careful
performance reporting, auditing generalizability, documentation, and regulation.
6.1. Quantifying Impact
Unlike in other settings with high-stakes decisions, e.g., aviation, clinical staff performance
is not audited by an external body (122). Instead, clinicians are often a self-governing
body, relying on clinicians themselves to determine when a colleague is underperforming or
in breach of ethical practice principles, e.g., through such tools as surgical morbidity and
mortality conferences (123). Clinical staff can also struggle to keep abreast of what current
best practice recommendations are, as these can change dramatically over time; one study
found that more than 400 previously routine practices were later contradicted in leading
clinical journals (124).
Hence, it is important to measure and address the downstream impact of models though
audits for bias and examination of clinical impact (6). Regular “auditing” post-deployment,
i.e., detailed inspection of model performance on various groups and outcomes, may reveal
the impact of models on different populations (8) and identify areas of potential concern.
Some recent work has targeted causal models in dynamic systems in order to reduce the
severity of bias (125). Others have targeted bias reduction through model construction
with explicit guarantees about balanced performance (16), or specifying groups which must
have equal performance (126). Additionally, there is the possibility that models may help
to de-bias current clinical care by reducing known biases against minorities (127) and dis-
advantaged majorities (128).
Model auditing: The
post-deployment
inspection of model
performance on
groups and outcomes
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6.2. Model Generalizability
As has been raised in previous sections, a crucial concern with model deployment is gener-
alization. Any shifts in data distributions can significantly impact model performance when
the settings for development and for deployment differ. For example, chest X-ray diagnosis
models can have high performance on test data drawn from the same hospital but degrade
rapidly on data from another hospital (129). Other work in gender bias on chest X-ray data
has demonstrated both that small proportions of female chest x-rays degrades diagnostic
performance accuracy in female patients (130), and that this is not simply addressed in all
cases by adding in more female X-rays (131). Even within a single hospital, models trained
on data from an initial EHR system data deteriorated significantly when tested on data
from a new EHR system (132). Finally, data artifacts that induce strong priors in what
patterns ML models are sensitive to have the potential to perpetrate harms when used
without awareness (133). For example, patients with dark skin can have morphological
variation and disease manifestations that are not easily detected under the defaults that
are set by predominantly white-skinned patients (134).
Generalizability: The
ability of a model to
apply in a setting
different from the
one in which it was
trained
Data artifact: A flaw
in data caused by
equipment,
techniques, or
conditions that is
unrelated to model
output
Several algorithms have recently been proposed to account for distribution shift in
data (135, 136). However, these algorithms have significant limitations as they typically
require assumptions about the nature or amount of distributional shift an algorithm can
accommodate. Some, like (136), may require a clear indication of which distributions in
a health care pipeline are expected to change, and develop models for prediction accord-
ingly. Many of these assumptions may be verifiable. If not, periodically monitoring for data
shifts (137), and potentially retraining models when performance deteriorates due to such
shifts is an imperative deployment consideration with significant ethical implications.
6.3. Model and Data Documentation
Clear documentation enables insight into the model development and data collection. Good
model documentation should include clinically specific features of model development that
can be assessed and recorded beforehand, such as logistics within the clinical setting, po-
tential unintended consequences, and trade-offs between bias and performance (138). In
addition to raising ethical concerns in the pipeline, the process of co-designing “checklists”
with clinical practitioners formalizes ad-hoc procedures and empowers individual advo-
cates (139). Standardized reporting of model performance—such as the one-page summary
“model cards” for model reporting (140)—can empower clinical practitioners to understand
model limitations and future model developers to identify areas of improvement. Similarly,
better documentation of the data supporting initial model training can help expose sources
of discrimination in the collected data. Modelers could use “datasheets” for datasets to
detail the conditions of data collection (141).
6.4. Regulation
In the United States, the Food and Drug Administration (FDA) has responsibility for the
regulation of health care ML models. As there does not exist comprehensive guidance for
health care model research and subsequent deployment, the opportunity is ripe to create
a comprehensive framework to audit and regulate models. Currently, the FDA’s proposed
ML-specific modifications to the software as a medical device (SaMD) regulations draw a
distinction between models that are trained and then frozen prior to clinical deployment
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Figure 2
The model development pipeline contains many challenges for ethical machine learning for health
care. We highlight both visible and hidden challenges.
and models that continue to learn on observed outcomes. Although models in the latter
class can leverage larger, updated datasets, they also face additional risk due to model drift
and may need additional audits (142). Such frameworks should explicitly account for health
disparities across the stages of ML development in health, and ensure health equity audits
as part of postmarket evaluation (143). We also note that there are many potential legal
implications, e.g., in malpractice and liability suits, that will require new solutions (144).
Researchers have proposed additional frameworks to guide clinical model development,
which could inspire future regulation. ML model regulation could draw from existing reg-
ulatory frameworks: a randomized controlled trial for ML models would assess patient
benefit compared to a control cohort of standard clinical practice (145), and a drug de-
velopment pipeline for ML models would define a protocol for adverse events and model
recalls (146). The clinical interventions accompanying the clinical ML model should be
analyzed to contextualize the use of the model in the clinical setting (147).
7. RECOMMENDATIONS
In this review, we have described the ethical considerations at each step of the ML model
development pipeline we introduced. While most researchers will address known challenges
like deployed task accuracy and outcome distribution shift, they are unlikely to be aware
of the full magnitude of the hidden challenges such as existing health inequities or outcome
label bias. As seen in Figure 2, many hidden pipeline challenges can go unaddressed in a
typical ML health project, but have serious ethical repercussions. With these challenges in
mind, we propose five general recommendations that span the pipeline stages.
1. Problems should be tackled by diverse teams and using frameworks that increase the
probability that equity will be achieved. Further, historically understudied problems
are important targets to practitioners looking to perform high-impact work.
2. Data collection should be framed as an important front-of-mind concern in the ML
modelling pipeline including clear disclosures about imbalanced datasets, and re-
searchers should engage with domain experts to ensure that data reflecting under-
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served and understudied populations’ needs are gathered.
3. Outcome choice should reflect the task at hand and should preferably be unbiased. If
the outcome label has ethical bias, the source of inequity should be accounted for in
ML model design, leveraging literature that attempts to remove ethical biases during
pre-processing, or with use of a reasonable proxy.
4. Reflection on the goals of the model is essential during development, and should be
articulated in a pre-analysis plan. In addition to technical choices like loss function,
researchers must interrogate how, and whether, a model should be developed to best
answer a research question, and what caveats are included.
5. Audits should be designed to identify specific harms, and paired with methods and
procedures. Harms should be examined group-by-group, rather than at a population
level. ML ethical design “checklists” are one possible tool to systematically enumerate
and consider such ethical concerns prior to declaring success in a project.
Finally, we note that machine learning also could and should be harnessed to create
shifts in power in health care systems (148). This might mean actively selecting problems
for the benefit of underserved patients, designing methods to target systemic interven-
tions for improved access to care and treatments, or enforcing evaluations with the explicit
purpose of preserving patient autonomy. In one salient example, the state of California
reduced disparities in rates of obstetric hemorrhage (and therefore maternal mortality for
women of color) by weighing blood loss sponges, i.e., making access to treatment consis-
tent and unbiased for all women (149). Models could similarly be harnessed to learn and
recommend consistent rules, giving researchers a potential opportunity to de-bias current
clinical care (150), measure racial disparities and mistrust in end-of-life care (82), improve
known biases against minorities (127) and disadvantaged majorities (128). Ultimately, the
responsibility for ethical models and behavior lies with a broad community, but begins with
technical researchers fulfilling an obligation to engage with patients, clinical researchers,
staff, and advocates to build ethical models.
FUTURE QUESTIONS
1. How can we combat urgent global health crises that exacerbate existing patterns of
health injustices?
2. How can we encourage model developers to build ethical considerations into the
pipeline from the very beginning? Currently, when egregious cases of injustice are
discovered only after clinical impact has already occurred, what can developers do
to engage?
3. How can evaluation and audits of ML systems be translated into meaningful clinical
practice when, in many countries, clinicians themselves are subject to only limited
external evaluations or audits?
4. When, if ever, should sensitive attributes like race be used in analysis? How should
we incorporate socially constructed features into models and audits?
5. How can ML be used to shift power, e.g., from well-known institutions, privileged
patients, and wealthy multinational corporations to the patients most in need?
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